View Exam | PowerPak

1. LS is a 43-year-old male with a history of multiple sclerosis (MS). He was previously treated with glatiramer acetate for 3 years but experienced 4 relapses in that time. His therapy was switched to ocrelizumab after consultation with his providers. During his first infusion, LS experienced pruritus, erythema, and flushing and reported a moderate headache. He tells his medical team that he is skeptical about continuing with the new medication because of the adverse side effects he experienced. According to the information in this case, which of the following would be the best option for a specialty pharmacist to increase the likelihood of LS's adherence to his new therapy?

A. Provide education on how infusions work B. Provide education on the risks of infusion therapy C. Initiate a different disease-modifying therapy D. Make sure the pre-medications were given before the first infusion and make sure they will be given before the next infusion E. Unsure

2. Which of the following are components of specialty pharmacy?
I. Medication access specialists
II. Formulary specialists
III. All are Medicaid programs
IV. Patient management programs
V. Responsible for medication trouble-shooting

A. I and II B. I, IV, and V C. I, III, IV, and V D. III, IV, and V E. Unsure

3. Which of the following clinical features is associated with poor outcomes in multiple sclerosis?

A. Caucasian race B. Young age at presentation C. Presence of spinal cord disease D. Good recovery after first relapse E. Unsure

4. Which of the following is considered “no evidence of disease activity” (NEDA) in multiple sclerosis (MS)?

A. No evidence of clinical relapses or magnetic resonance imaging (MRI) lesions B. No evidence of clinical progression or MRI lesions C. No evidence of relapses, cortical atrophy, or MRI lesions D. No evidence of relapses, clinical progression, or MRI lesions E. Unsure

5. MD is a 25-year-old female recently diagnosed with relapsing-remitting multiple sclerosis (RRMS) and would like to become more knowledgeable about her disease state. She asks her team who are caring for her multiple sclerosis (MS) several questions, which follows the model for shared decision-making, including sharing the following statements she found while gathering information on the internet. Which statement is FALSE?

A. Brain reserve is the ability to tolerate the age-related changes and the disease-related pathology in the brain without developing clear clinical symptoms or signs B. Most approved MS therapies have proven efficacy in delaying disease progression measured by clinical relapses and magnetic resonance imaging activity C. Fingolimod is approved in the United States for patients with primary-progressive MS (PPMS) D. Ocrelizumab is approved in the United States for patients with PPMS E. Unsure

Evaluation Questions

6. How confident are in your treatment choice for LS in the post-test?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Which of the following are components of specialty pharmacy?
I. Medication access specialists
II. Formulary specialists
III. All are Medicaid programs
IV. Patient management programs
V. Responsible for medication trouble-shooting

3. Which of the following clinical features is associated with poor outcomes in multiple sclerosis?

4. Which of the following is considered “no evidence of disease activity” (NEDA) in multiple sclerosis (MS)?

Evaluation Questions

6. How confident are in your treatment choice for LS in the post-test?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Which of the following are components of specialty pharmacy? I. Medication access specialists II. Formulary specialists III. All are Medicaid programs IV. Patient management programs V. Responsible for medication trouble-shooting

3. Which of the following clinical features is associated with poor outcomes in multiple sclerosis?

4. Which of the following is considered “no evidence of disease activity” (NEDA) in multiple sclerosis (MS)?

Evaluation Questions

6. How confident are in your treatment choice for LS in the post-test?

« Return to Activity

Customers who Purchased
this Activity also Purchased

2. Which of the following are components of specialty pharmacy?
I. Medication access specialists
II. Formulary specialists
III. All are Medicaid programs
IV. Patient management programs
V. Responsible for medication trouble-shooting